Improved Glycemia with Hybrid Closed-Loop (HCL) Versus Continuous Subcutaneous Insulin Infusion (CSII) Therapy: Results from a Randomized Controlled Trial.
暂无分享,去创建一个
Gregory P. Forlenza | J. McGill | M. Lawson | R. Vigersky | B. Buckingham | R. Slover | I. Hirsch | Y. Kudva | S. Garg | L. Dimeglio | G. Grunberger | G. Forlenza | John J. Shin | B. Bode | R. Pop-Busui | A. Rhinehart | R. Weinstock | R. Brazg | T. Cordero | Scott W. Lee | A. Philis-Tsimikas | M. Kipnes | Mark P. Christiansen | A. Criego | Anders L. Carlson | K. Kaiserman | Chenxiao Ling | Ashleigh Keiter | David R Lilenquist | K. Griffin | B. Marinos
[1] D. Bruttomesso,et al. Switching from predictive low glucose suspend to advanced hybrid closed loop control: effects on glucose control and patient reported outcomes. , 2022, Diabetes research and clinical practice.
[2] B. Buckingham,et al. Glycemic outcomes of children 2–6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial , 2022, Pediatric diabetes.
[3] Z. Fang,et al. Efficacy and safety of closed-loop insulin delivery versus sensor-augmented pump in the treatment of adults with type 1 diabetes: a systematic review and meta-analysis of randomized-controlled trials , 2021, Journal of Endocrinological Investigation.
[4] R. Beck,et al. Real-world, Patient-Reported and Clinic Data from Individuals with Type 1 Diabetes using the MiniMed 670G Hybrid Closed Loop System. , 2021, Diabetes technology & therapeutics.
[5] John J. Shin,et al. Real‐world performance of the MiniMed™ 670G system in Europe , 2021, Diabetes, obesity and metabolism.
[6] Pearl L. Yu,et al. The Impact of a Recently Approved Automated Insulin Delivery System on Glycemic, Sleep, and Psychosocial Outcomes in Older Adults With Type 1 Diabetes: A Pilot Study , 2021, Journal of diabetes science and technology.
[7] Lauren M. Huyett,et al. First Outpatient Evaluation of a Tubeless Automated Insulin Delivery System with Customizable Glucose Targets in Children and Adults with Type 1 Diabetes , 2020, Diabetes technology & therapeutics.
[8] Sybil A. McAuley,et al. Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial , 2020, Diabetes Care.
[9] Erin C. Cobry,et al. Impact of the Hybrid Closed-Loop System on Sleep and Quality of Life in Youth with Type 1 Diabetes and their Parents. , 2020, Diabetes Technology & Therapeutics.
[10] P. Beato-Víbora,et al. Prospective analysis of the impact of commercialised hybrid closed-loop system on glycaemic control, glycaemic variability and patient-related outcomes in children and adults: a focus on superiority over predictive low glucose suspend technology. , 2019, Diabetes technology & therapeutics.
[11] R. Bergenstal,et al. Advanced Technology in the Management of Diabetes: Which Comes First—Continuous Glucose Monitor or Insulin Pump? , 2019, Current Diabetes Reports.
[12] J. Snell-Bergeon,et al. Glycemic Outcomes with Early Initiation of Continuous Glucose Monitoring System in Recently Diagnosed Patients with Type 1 Diabetes. , 2019, Diabetes technology & therapeutics.
[13] B. Buckingham,et al. Safety Evaluation of the MiniMed 670G System in Children 7–13 Years of Age with Type 1 Diabetes , 2019, Diabetes technology & therapeutics.
[14] B. Buckingham,et al. Psychosocial and Human Factors During a Trial of a Hybrid Closed Loop System for Type 1 Diabetes Management. , 2018, Diabetes technology & therapeutics.
[15] John J. Shin,et al. Retrospective Analysis of 3-Month Real-World Glucose Data After the MiniMed 670G System Commercial Launch. , 2018, Diabetes technology & therapeutics.
[16] Wei Bao,et al. Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: population based study , 2018, British Medical Journal.
[17] Gregory P. Forlenza,et al. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial , 2018, Diabetes Care.
[18] D. Maahs,et al. Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: International comparison from the T1D Exchange and DPV Initiative , 2018, Pediatric diabetes.
[19] Bruce R King,et al. Reduction in Hypoglycemia With the Predictive Low-Glucose Management System: A Long-term Randomized Controlled Trial in Adolescents With Type 1 Diabetes , 2017, Diabetes Care.
[20] W. Tamborlane,et al. Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study , 2017, Diabetes Care.
[21] R. Hovorka,et al. Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial Substudy , 2017, Journal of diabetes science and technology.
[22] Benyamin Grosman,et al. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes , 2017, Diabetes technology & therapeutics.
[23] John B. Welsh,et al. Effectiveness of Automated Insulin Management Features of the MiniMed® 640G Sensor-Augmented Insulin Pump , 2016, Diabetes technology & therapeutics.
[24] J. Lachin,et al. Mortality in Type 1 Diabetes in the DCCT/EDIC Versus the General Population , 2016, Diabetes Care.
[25] S. Garg,et al. Hypoglycemia Reduction and Changes in Hemoglobin A1c in the ASPIRE In-Home Study , 2015, Diabetes technology & therapeutics.
[26] B. Zinman,et al. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. , 2015, JAMA.
[27] P A Cleary,et al. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). , 2001, The Journal of pediatrics.
[28] W. Tamborlane,et al. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. , 1999, Diabetes care.